Brief: Shanghai Henlius Biotech Says Phase 2/3 Trial Of HLX07 With Hansizhuang For Advanced SQNSCLC Approved To Commence In Australia
24/04/2026 11:59
April 24 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: PHASE 2/3 TRIAL OF HLX07 WITH HANSIZHUANG FOR ADVANCED SQNSCLC APPROVED TO COMMENCE IN AUSTRALIA Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln